"Treatment"

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

There are many diseases that may recur after treatment, so many head and neck cancer patients are worried about such a situation, and their frequent ruminations may cause a lot of psychological stress to them.

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.

Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.